SEARCH

SEARCH BY CITATION

Abstract

One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human γ-interferon (rHuγ-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHuγ-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHuγ-IFN was greater than that with placebo, the differences were generally not statistically significant.